Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate

Osteoporosis International

Volumn 18, Issue 10, 2007, Pages 1435-1438

  Pascual, J ^a,b   Torrealba, J ^a   Myers, J ^a   Tome, S ^a   Samaniego, M ^a   Musat, A ^a   Djamali, A ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

Alendronate; Bisphosphonate; Chronic kidney disease; Nephrotic syndrome; Osteopenia

Indexed keywords

ALENDRONIC ACID; ENALAPRIL; INSULIN; LOSARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; PAMIDRONIC ACID; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; BONE DENSITY; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLOMERULOSCLEROSIS; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; LABORATORY TEST; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MALE; MORBIDITY; OSTEOPENIA; PRIORITY JOURNAL; SYSTEMIC CIRCULATION;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY FAILURE, CHRONIC; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROTEINURIA; TREATMENT OUTCOME;

EID: 34548089752     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-007-0361-9     Document Type: Article

References (20)

1. Leidig-Bruckner G, Hosch S, Dodidou P et al (2001) Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 357:342-347
2. Millonig G, Graziadei IW, Eichler D et al (2005) Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl 11:960-966
3. Dodidou P, Bruckner T, Hosch S et al (2003) Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Osteoporos Int 14:82-89
4. Laurinavicius A, Hurwitz S, Rennke HG (1999) Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study. Kidney Int 56:2203-2213
5. Markowitz GS, Appel GB, Fine PL et al (2001) Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12:1164-1172
6. Kunin M, Kopolovic J, Avigdor A et al (2004) Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient. Nephrol Dial Transplant 19:723-726
7. Barri YM, Munshi NC, Sukumalchantra S et al (2004) Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 65:634-641
8. Bounameaux HM, Schifferli J, Montani JP et al (1983) Renal failure associated with intravenous diphosphonates. Lancet 1:471
9. Yates AJ, Percival RC, Gray RE et al (1985) Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet 1:1474-1477
10. Dumon JC, Magritte A, Body JJ (1991) Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia. Bone Miner 15:257-266
11. Barisoni L, Kriz W, Mundel P et al (1999) The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 10:51-61
12. Sauter M, Julg B, Porubsky S et al (2006) Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept? Am J Kidney Dis 47:1075-1080
13. Markowitz GS, Fine PL, D'Agati VD (2002) Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis 39:1118-1122
14. Markowitz GS, Fine PL, Stack JI et al (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64:281-289
15. Giannini S, D'Angelo A, Carraro G et al (2001) Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 16:2111-2117
16. Jeffery JR, Leslie WD, Karpinski ME et al (2003) Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation 76:1498-1502
17. Shane E, Addesso V, Namerow PB et al (2004) Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 350:767-776
18. Haagsma EB, Thijn CJ, Post JG et al (1988) Bone disease after orthotopic liver transplantation. J Hepatol 6:94-100
19. Meys E, Fontanges E, Fourcade N et al (1994) Bone loss after orthotopic liver transplantation. Am J Med 97:445-450
20. Pillebout E, Nochy D, Hill G et al (2005) Renal histopathological lesions after orthotopic liver transplantation. Am J Transplant 5:1120-1129